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From as early as 2005, different guidelines and quality standards covering biobank
activities and sample handling methods have been developed to improve and guarantee
the reproducibility of biomarker research. Ten years on, the BBMRI.be Quality working
group wanted to gauge the current situation of these aspects in the biobanks of the
BBMRI.be network. To this end, two online surveys were launched (fall 2017 and fall
2018) to the biobank quality managers in the BBMRI.be network to determine the
status and setup of their current quality management system (QMS) and how their
QMS and related practices have evolved over a 14 month time period. All biobanks
addressed by the two surveys provided a complete response (12 and 13, respectively).
A QMS was implemented in 85% of biobanks, with 4 standards emerging as primary
basis. Supplementary guidelines were used, with a strong preference for the ISBER
best practices for biobanks. The Standard Preanalytical Code—an indicator of the
preanalytical lifecycle of a biospecimen impacting the downstream analysis results—was
already implemented in 50% of the biobanks while the other half intends future
implementation. To assess and maintain the quality of their QMS, 62% of biobanks
used self-assessment tools and 71% participated in proficiency testing schemes. The
majority of biobanks had implemented procedures for general and biobank specific
activities. However, policies regarding the business and sustainability aspect of biobank
were only implemented in a limited number of biobanks. A clear desire for a peer-
review audit was expressed by 69% of biobanks, with over half of them intending to
implement the recently published biobank standard ISO20387. Overall, the biobanks
of the BBMRI.be network have actively implemented a solid quality approach in their
practices. The implementation of ISO 20387 may bring further professionalization of
activities. Based on the needs expressed in this survey, the Quality working group will
be setting up an audit program for the BBMRI.be biobanks, to enhance, harmonize and
streamline their activities. On the whole, the biobanks in the BBMRI.be network are able
to substantially contribute to translational research, as a primary facilitator guaranteeing
high quality standards and reproducibility.
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INTRODUCTION
Irreproducibility of results has been identified as a major
undermining factor for translating research results into clinical
applications (1). Different categories of errors contribute to
this irreproducibility, with biological reagents and reference
materials having the biggest impact (2). It has also been shown
that standardization and auditing of biological materials—
through biological resource centers or biobanks—can enhance
cumulative production of scientific knowledge by improving
both availability and reliability of research inputs (3). This need
for biospecimen handling standards and the professionalization
of biobanking practices to improve research outcome was
recognized more than a decade ago. As early as 2005,
the “International Society for Biological and Environmental
Repositories” (ISBER) published the first version of their best
practices in order to support the increasing demands for specific
high quality biological material (4). Concurrently, different
organizations, biobank networks and national initiatives all
worked on best practices and guidelines to address the need
for more professionalized biobanking practices and quality
management systems (QMS) (5–9). Additionally, significant
effort has been put in creating technical standards for pre-
examination processes such as those developed within the
SPIDIA project (10, 11), for capturing pre-analytical factors such
as the Standard Pre-analytical Code (12, 13) and standardized
data collection (14–16) to allow fit-for-purpose biological
sample management. Finally, educational programs for biobank
personnel have been set-up to further professionalize the
discipline (17–19).
At the same time, three biobank networks were established in
Belgium: the Flemish Biobank Network (FBN) [formerly known
as the Center for Medical Innovation (CMI)], the Belgian Virtual
Tumorbiobank (BVT), and the Biothèque Wallonie Bruxelles
(BWB). A common goal of these networks is to improve and/or
harmonize the quality of the biospecimens for the purpose of
high-quality collaborative research, albeit through a different
approach. The FBN was initiated in 2010 by the Center for
Medical Innovation (CMI, Flemish government). The CMI was
established to stimulate translational biomedical research and
to reach a significant economic value in Flanders by setting
up 4 clinical research centers within the Flemish universities
and university hospitals. The initial focus lay on advancing
biobank professionalization and harmonization within Flanders
for five focus disease domains (inflammatory bowel disease,
rheumatoid arthritis, diabetes type I, sudden cardiac death
and hepatological/hepatotropic diseases). Apart from defining
local ethical and legal guidelines, a key result of the CMI
initiative was the publication and implementation of the uniform
CMI biobank quality guidelines. These were based on the ISO
9001:2008 standard and the OECD guidelines for biorepositories
and allowed standardization within the Flemish biobanks. All
biobanks of the network were peer-review audited in 2014
according to the CMI quality guidelines. In parallel, a minimal
data set of 14 attributes was defined to enable the setup
of a centralized virtual catalog for sample query to facilitate
collaboration within the five focus domains. In analogy to
the FBN network, the BWB project was set up in 2012,
incorporating the academic biobanks in Wallonia and Brussels,
with the objective of providing a virtual catalog of biospecimens
to facilitate translational research. The BWB also established
QMS guidelines for biobanks, initially based on the guidelines
previously defined by the FBN, which have been used by the
BWB biobanks as a basis for their QMS. The BVT was created in
2008 as part of the Belgian National Cancer Plan, which intended
to fight cancer by integrating all aspects of the fight against
the disease. The aim of the BVT is to centralize standardized
and curated data of available residual human tumor samples,
collected in the university hospitals and liaised laboratories, in
an easy lookup tool. The pseudonymized database is accessible
for researchers to query and trace their samples of interest to
the local biobanks of the network, where the samples can be
released for research projects. Additionally, the BVT also strives
to optimize quality by creating awareness about data quality
and sample collection by incorporating these elements in the
requested standardized dataset.
Since 2013, these three biobank networks are participating
in BBMRI.be, the national node of the European Research
Infrastructure BBMRI-ERIC, effectively gathering 13 biobanks
within one network. Within this national node of BBMRI.be, a
Quality working group was established with the aim to define
a consensus approach to harmonized QMS systems, biobank
sample flows and procedures based upon existing international,
European, Belgian and regional requirements. Ten years after the
start-up of the Belgian biobank networks, the BBMRI.be Quality
working group wanted to gauge the current quality status of the
connected biobanks, to define the areas of improvement within
the biobanks and to develop tailored support by the Quality
working group. To this end, we launched 2 online surveys (fall
2017 and fall 2018) to the biobank quality managers (12 and 13,
respectively) in the BBMRI.be network to determine the status
and setup of their current QMS and how their QMS and related
practices have evolved over a 14 month time period.
MATERIALS AND METHODS
First Survey
Fall 2017, a short, high level questionnaire made using the
SurveyMonkeyTM tool was distributed to the quality managers
of biobanks linked to BBMRI.be to assess the general status and
activities with respect to the QMS. The survey was distributed
to the 12 biobanks of the BBMRI.be network, by providing a
link in an explanatory email. For those biobanks which did not
have a separate quality manager (e.g., due to limited biobank staff
size), the general biobank manager was addressed. The survey
questions are available in the Supplementary Material.
Second Quality Survey
The second, more detailed Quality survey was designed using
REDCap electronic data capture tools hosted at Ghent University
Hospital. REDCap (Research Electronic Data Capture) (20)
is a secure, web-based application designed to support data
capture for research studies, providing: (1) an intuitive interface
for validated data entry; (2) audit trails for tracking data
Frontiers in Medicine | www.frontiersin.org 2 June 2019 | Volume 6 | Article 141
Linsen et al. Belgian Biobank Quality Management
FIGURE 1 | The set-up and composition of human body material collections in biobanks of the BBMRI.be network. Responses were divided by the nature of the
human body material collection (collection with a disease orientation, population-based or on environmental ground), by the method of collection of the material
(systematic i.e., by sampling at occasions within the clinical path of the patient or project-based i.e., by sampling in the framework of a specific study/project at
pre-defined and study-based time points) and by the type of use as defined in the Belgian legislation (primary use: the use to which the donor has explicitly consented
to at the time of collection; secondary use: any other use than the one consented to at the time of collection; residuary material: the portion of human bodily material
that has been taken from the donor for diagnostic or treatment purposes which, when a sufficient sample is safeguarded for refinement or completion of these
purposes, is superfluous to these purposes and as such could be destroyed—presumed consent applies).
manipulation and export procedures; (3) automated export
procedures for seamless data downloads to common statistical
packages; and (4) procedures for importing data from external
sources. The survey was distributed to the 13 (2018) biobanks
of the BBMRI.be network, by providing a link in an explanatory
email. The survey consisted of a dynamical questionnaire,
visualizing additional questions dependent on the responses
given to deepen the answers given to the core set of questions. The
content focused on threemain sections. The first section captured
the general information of the biobank and the QMS system.
The second part focused on the specific procedures present in
the QMS system and the supportive systems used. The third
part addressed the needs related to Quality of the BBMRI.be
biobank community. The survey questions are available in the
Supplementary Material.
Survey Analysis
The survey data of both surveys was exported into a spreadsheet
and data analysis was performed using the REDCap data analysis
tool combined with Sigmaplot for graph design.
RESULTS
Properties of BBMRI.be Biobanks
After sending out the surveys, all quality/biobank managers
(respectively, 12/12 in 2017 and 13/13 in 2018) targeted in the
mailing submitted a complete set of responses for the two online
questionnaires. Themajority of biobanks were university hospital
integrated (9/13). The responders also included 1 academic
biobank, 1 general hospital-based biobank and 2 biobanks of
research institutions (type non-profit organization or association
without lucrative purpose). The responders are biobanks with
multiple types of collections in their catalog, as can be seen in
Figure 1. These collections are mainly disease-oriented (92%)
and originate from both systematic (92%) and project/study
based (77%) approaches to sample collection. All of the biobanks
collect residuary material cleared by presumed consent, in
compliance to current Belgian legislation. In addition, 69% of
biobanks collect samples for primary use and 54% of biobanks
also distribute samples for secondary use (defined by Belgian law
as any use different from that to which was consented by the
donor at the time of collection of the specimen).
Of the 13 responders, 8 biobanks are part of a
certified/accredited lab environment (60% ISO 15189, 10%
ISO 17025). Three biobanks had obtained an ISO 9001 certificate
specifically for their biobanking activities. Sixty two percent of
the responders receive samples of an accredited lab environment
[Pathology lab (ISO 15189), Clinical-Analytic lab (ISO 17025) or
Medical Genetics lab (ISO 15189) or JACIE accredited facility].
QMS Status and Sources of
Belgian Biobanks
At the time of the first survey in the fall of 2017, 11 out of 12
participating biobanks had implemented a QMS. By the time
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of the second survey, about 1 year later, 85% of the biobanks
have implemented an operational QMS system. The remaining
15% of responders is currently in the process of implementing
a QMS system. Four guidelines stand out as primary basis for
FIGURE 2 | Quality standards or guidelines used as primary basis for the
quality management system of the biobanks in the BBMRI.be network.
Participants were asked to select the standard or guideline used as primary
basis for their QMS from a list of nine standards/guidelines (ISO 9001, ISO
15189, ISO 17025, ISO 20387, CMI QMS Guidelines, BWB QMS Guidelines,
ISBER Best Practices, OECD Recommendations for Biorepositories, French
Biobanking standard NF S96-900). Only one option could be selected. Only
four standards/guidelines were indicated by the responders to be used as
primary basis for QMS systems, as displayed in the figure. QMS, quality
management system.
the QMS: ISO 9001 (31%), CMI quality guidelines (31%), ISO
15189 (23%), and the BWB quality guidelines (15%) (Figure 2).
Apart from one biobank, all biobanks use additional guidelines
for their QMS (Table 1). The most frequently used are the ISBER
guidelines for biobanks (69%), the ISO 9001 standard (67%),
and the OECD guidelines for biorepositories (54%). Fifty percent
of responders applied the Standard Pre-analytical Code, either
automatically (33%), or manually (17%), while the other half
intended to implement SPREC in the future. Only 1 responder
had implemented BRISQ and only 1 responder intended to
implement it in the future (data not shown).
At the time of the first survey, a majority (73%) had never
taken part in freely available online self-assessment surveys (SAS)
(9% had taken the ISBER SAS, 18% the BBMRI-ERIC general
QMS SAS or the BBMRI-ERIC SAS to check compliance to
the CEN technical standards for pre-examination processing of
biospecimens). One year on, 62% of responders are using one or
more self-assessment tools. The BBMRI-ERIC general QMS SAS
(63%) and the ISBER SAS (50%) are the most commonly applied
tools in the BBMRI.be network (Figure 3).
Fall 2018, 54% of the responders was participating in yearly
external proficiency testing for their testing or processing
methods. Of these responders, 71% is using biobank specific
proficiency testing programs (such as the IBBL proficiency
testing program), which is an increase compared to the number
reported the year before (46%). Biobanks embedded in accredited
laboratories can participate in laboratory related proficiency
schemes and 43% of the biobanks make use of this possibility
(data not shown). Several reasons were given for not participating
in the biobank specific proficiency testing schemes: (i) it is not
requested by the providers or customers (4/6), (ii) the high
cost of participation (2/6), (iii) the lack of added value for the
biobank (1/6), and (iv) the adequacy of available biobank testing
schemes (1/6).
TABLE 1 | Primary and secondary QMS standards and guidelines used in Belgian biobanks.
Responder ISO 9001 ISO 15189 ISO 17025 ISO 20387 CMI QMS guidelines BWB QMS guidelines ISBER OECD NF S96-900
1 Prim Sec – Sec – Sec Sec Sec –
2 Prim Sec Sec Sec Sec – Sec Sec Sec
3 Prim – – – – – – – –
4 Prim – – – – Sec – – –
5 Sec Prim Sec – Sec – Sec Sec –
6 Sec Prim – Sec – Sec Sec Sec Sec
7 – Prim – – – Sec Sec Sec Sec
8 Sec – – – Prim – – – –
9 Sec – – Sec Prim – Sec – –
10 Sec Sec – Sec Prim – Sec Sec Sec
11 – Sec Sec – Prim – Sec Sec –
12 – – – – – Prim Sec – –
13 Sec – – – - Prim – – –
Total # of QMS standard use 10 7 3 5 6 6 9 7 4
# of secondary QMS standard use 6 4 3 5 2 4 9 7 4
Prim, standard/guideline used as primary basis for QMS; Sec, standard/guideline used as supplementary basis for QMS; QMS, Quality Management System.
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FIGURE 3 | Use of self-assessment tools in biobanks in the BBMRI.be
network in 2017 and 2018. Participants were asked to indicate from a list
which self-assessment survey (SAS) tools were used in their biobank to assess
the status of the overall quality management system (BBMRI-ERIC
QMS—general requirements and ISBER SAS), the compliance to standard
specifications for pre-examination processes (CEN/TS aggregated: 10
individual SAS tools developed by BBMRI-ERIC, participation in one or more
of these SAS tools was considered as 1 positive reply), the overall quality
status of the pre-analytical processes (ISBER EQAS) or awareness of factors in
tissue collection, processing and storage that may impact sample quality (CM
Path Biobanking SQIT). Black bars indicate participants’ responses in 2017,
gray bars indicate participants’ responses in 2018. CEN/TS, European
Committee for Standardization Technical Standards; EQAS, pre-analytical
external quality assessment survey; SQIT, CM-Path Biobanking Sample
Quality Improvement Tool.
Status of QMS and Biobank Requirements
in BBMRI.be Biobanks
In the questionnaire, an aggregated list of required procedures
for ISO 9001:2015, ISO 20387:2018, and the ISBER best
practices (fourth edition) was presented to the participants. An
overview of the responses regarding the general and biobank
specific procedures and requirements is shown in Figures 4,
5, respectively.
Eight out of 17 general QMS requirements are fulfilled
by more than 80% of responders and an additional 6 have
been implemented by 60–80% of responders. Two items have
been implemented by 40–60% of responders (i.e., contingency
plan and customer satisfaction & compliant handling) and
1 item was available in <40% of responding biobanks (i.e.,
impartiality statement). When also taking the responders into
account where the procedures were in preparation, 12 out of 17
requirements were being addressed by over 80% of responders.
Again the impartiality statement was the least addressed, whereas
the contingency plan, customer satisfaction and complaint
handling, personnel recruitment and management review were
the procedures that were proportionally less present (Figure 4).
FIGURE 4 | Implementation status of general procedures in the quality
management system in biobanks in the BBMRI.be network. Participants were
requested to indicate for each item in a list of general procedures/items
whether these were fully implemented (brown), in preparation (orange) or not
available (lime-green). The items listed were collected and aggregated from the
ISBER best practices for biorepositories, the ISO 20387 and ISO 9001
standards. All participants responded to all items listed. The list of items asked
is displayed in the X-axis.
Regarding the biobank specific requirements, 8 out of 16 items
had been implemented by >80% of responders at the time of the
survey, 5 by 60–80%, 1 by 40–60% (contracts for collaborators)
and 2 by 20–40% (quality control of methods/processes and
quality control of data). The procedure for storage of human
bodily material was present in all biobanks. When taking into
account the responders that are in implementation phase for
the procedures, 16 out of 17 items were being addressed in
more than 80% of biobank QMS. The remaining item, quality
deviations or corrective/preventive actions, was reported in
60–80% of responders (Figure 5). One biobank indicated that
quality control of human bodily material or quality control of
methods/processes was not applicable for their activities.
Supportive systems used to handle these processes contained
in these procedures are present in at least 60% of responders,
although only document management and audit follow up
systems are used at over 80% of biobanks (Figure 6). Risk
management systems and provider/customer management
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FIGURE 5 | Implementation status of biobank specific procedures in biobanks
in the BBMRI.be network. Participants were requested to indicate for each
item in a list of specific procedures/items whether these were fully
implemented (brown), in preparation (orange), not available (lime-green), or not
applicable (dark green). The items listed were collected and aggregated from
the ISBER best practices for biorepositories, the ISO 20387 and ISO 9001
standards. All participants responded to all items listed. The list of items asked
is displayed in the X-axis.
systems are the least available. Predominantly electronic/digital
systems are utilized, although paper-based systems still occur for
document management, audit follow-up, risk management and
provider/customer management.
Future Goals and Needs of the
Belgian Biobanks
Finally, the intentions and perspectives of Belgian biobanks
were assessed. Sixty nine percent of the responders indicate to
strive for biobank certification and/or accreditation within 2
years, as can be seen in Figure 7. Although the percentage of
biobanks intending to acquire certification is similar to the one
indicated the year before (75%), the intended certification has
shifted. In 2017, 42% of biobanks aimed for both ISO 9001 and
ISO 20387 certification, 25% for ISO 20387 and 8% for ISO
9001 certification, while in 2018 this has focused to nearly 38%
intending ISO 20387 certification, 23% ISO 9001, and only 8%
of responders still intending to acquire both ISO 9001 and ISO
FIGURE 6 | Overview of systems used to support activities in biobanks in the
BBMRI.be network. Participants were asked to indicate in a list for which
supportive tools for the QMS an electronic system was implemented (brown),
a paper-based system was implemented (orange), an electronic system was in
preparation (lime-green), a paper-based system was in preparation (dark
green), or no system was available (petrol blue). All participants responded to
all items listed. The list of items asked is displayed in the X-axis.
20387 certification. About 31% of responders did not intend to
acquire certification.
The majority of responders (77%) indicated a clear need for a
Belgian SAS tool, adapted to the national biobank law which has
come into effect on November 1st 2018. The need for a national
proficiency program, on top of already existing schemes, was put
forward by 54% of the responders (data not shown).
An overwhelming majority (12/13) of the responders
expressed a need for the setup of a national peer-review audit
program. Several types of peer-review audit programs were
suggested: 75% of the responders would prefer a two-phase audit,
consisting of an initial administrative/documentary audit (off-
site) of the biobank procedures followed by a site visit 1 year later.
Twenty five percent of the responders would prefer a full on-site
audit straightaway.
DISCUSSION
Irreproducibility of results, also originating from the
biospecimens used, has been identified as a major undermining
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FIGURE 7 | Certification intentions biobanks in the BBMRI.be network.
Participants were asked to indicate which if any certification/accreditation they
intended to acquire within 2 years. Black bars show participants’ responses in
2017, gray bars show participants’ responses in 2018. All participants
responded to all items listed.
factor for translating research results into clinical applications.
Biobanks can play an important role by providing fit-for-purpose
(human) bodily material, governed through a professional QMS
according to evidence-based guidelines and/or standards.
Since 2013, the BBMRI.be network brings together the large
academic/non-profit research biobanks in Belgium and strives
through working groups for harmonization on multiple levels.
The BBMRI.be Quality working group setting new goals
in alignment with BBMRI-ERIC to further professionalize
qualitative biobanking in Belgium. To this end, the Quality
working group performed two surveys over the course of a year
to gauge the current quality status of the connected biobanks, to
define the areas of improvement in the biobanks themselves and
in the support delivered by the Quality working group.
The surveys were targeted to the Quality managers of the
biobanks or in absence of a dedicated person due to biobank
size, to the overall operational manager of the biobank. One
completed survey response was requested and received per
biobank. The biobanks show a big diversity in nature and
type of their collections. In the Belgian biobank legislation,
residual material can be obtained and used for research via an
opt out system (21), and a third of the BBMRI.be biobanks
consist entirely of residuary material collections. The use of
residuary material is not the default situation within the global
biobanking community, but it can show an impressive track
record of valuable results, provided certain quality and ethical
conditions are met (22). The results of this survey mainly reflect
the activities of academic research biobanks, which are currently
the main members of BBMRI.be. However, BBMRI.be intends
to represent the complete Belgian biobank landscape by also
reaching out to other institutional and/or commercial/private
biobanks in the near future, in an effort to address commonly
encountered biobank related issues. Uniting the Belgian biobanks
through BBMRI.be may also further improve and harmonize
biospecimen quality and consequentially contribute to an
increased reproducibility of translational research.
The survey results show that the BBMRI.be related biobanks
have a highly developed “quality” mindset, as the grand majority
of the biobanks have implemented a formal QMS and the
remaining biobanks are in progress of implementing a system.
The primary basis of the implemented QMS system is different
between the responders. This divergence has both historical and
organizational reasons. The FBN and the BWB were already
active and had published their quality handbooks before the
BBMRI.be community was set up. Additionally, biobanks that
are integrated in a ISO 15189 or ISO 17025 accredited laboratory
prefer to take this standard as primary basis of their QMS system.
Even so, all of the aforementioned guidelines/standards used
as a primary basis have a direct reference to ISO 9001, the
commonly accepted standard for general quality management
systems, indicating that the Belgian biobank QMS’s contain a
similar general basis for their activities and procedures.
The majority of biobanks take additional norms/guidelines
into account to develop their QMS. The variety of widely
available biobank guidelines is mirrored in the responses of the
participants, with the ISBER guidelines, the OECD guidelines
and ISO 9001 being the most popular. This diversity is
likely caused by the initial absence of a relevant international
norm covering all of the activities of a biobank (23), a gap
recently filled by the biobank centered ISO 20387 standard
(24). Despite its recent publication, it is already being picked
up by the biobanks in the BBMRI.be network. However,
the ISO 20387 standard was developed to be complementary
to and to be used with the existing biobank guidelines
from the start to strengthen a biobank’s pursuits for quality
management (25). This allows biobanks to tailor their own
needs but also leaves room for deviation based on the
guidelines used.
The majority of procedures for general and biobanking
specific activities, aggregated from the ISBER Best Practices
and the ISO 9001 and ISO 20387 standards, were present
in the BBMRI.be connected biobanks. The items with the
lowest compliance rates were either requirements from the
recently published biobanking ISO standard (e.g., impartiality
statement) or items that had received more focus due to the
publication of the standard (e.g., quality control of biospecimens
and/or methods/processes). The latter however are actively
being implemented by the non-compliant biobanks, indicating
that these have gained importance in the biobank activities.
In comparison to the results of the ISBER self-assessment
participants, the BBMRI.be biobanks score better at several
of the commonly asked items, both general and biobank
specific, again emphasizing the quality-mindset within the
participants (26).
We acknowledge that the results reported in this study are
self-reported and may therefore overestimate the actual status
of the responders’ QMS. However, the lagging of the business
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aspects of biobanking is in line with data from a recently
performed international study on biobank business operations
(27). Although this part of biobanking is an important factor
for success, it is a known gap in the community and the subject
has recently gained more visibility to professionalize this side of
biobank operations (28). Given the raised awareness regarding
this aspect in literature and biobank standards, we expect to see
progress in this area in future surveys.
Self-assessment tests and participation in proficiency testing
schemes are recognized ways to monitor the QMS controlled
activities and define areas for improvement. Initially these tools
were not very well-known within the biobanks of BBMRI.be, but
their participation rate has greatly increased over the 14 month
period covered by the surveys. One factor explaining this success
might be the indirect education through the surveys and the
presented first survey results.
Although most of the BBMRI.be biobanks indicate to use
the ISBER Best Practices as inspiration for their QMS, only
half of them have already taken the ISBER self-assessment
survey. Still, this is an increased proportion compared to
the 62 global biobanks that completed the full survey in
the period 2015–2017 (26). The biobanks might consider the
self-assessment as a premature activity, since some of the
essential biobank processes might still be in the implementation
phase. Additionally, diagnostic self-assessment surveys have
lost a bit of their appeal, with external audits gaining a
more apparent value. This is also reflected by the fact
that nearly all participants were in favor of setting up a
national peer-review audit program. Similar audit initiatives
have been and are being set-up in different national biobank
networks (29, 30), emphasizing the need felt by biobanks
to comply with the audit requirements stated by guidelines
and standards. Although these within-network audits have
the advantage of allowing to assess local legislative and
regulatory requirements, it may also introduce quality differences
between these networks. The European research infrastructure
BBMRI-ERIC therefore intends to setup a peer-review audit
program framework to be used by the member states, leaving
room for local peculiarities while maintaining an independent
comparative evaluation.
Peer-review audits can also serve as preparation for intended
certification or accreditation activities. With about three quarter
of participants intending to acquire certification for ISO 9001,
ISO 20387, or both within 2 years, the implementation of
a peer-review audit program might support the BBMRI.be
biobanks in achieving this goal. This intention is in line with
the ongoing evolution to “biobanking 3.0,” with an increased
focus on operational standardization of processes (31). A key
element initially unavailable to biobanks in this respect has
been quality assessment by an external organization (32). Two
currently available international programs show a high overall
success rate (33, 34). Furthermore, the new standard ISO 20387
will allow biobanks to pursue accreditation or certification
for their activities, formalizing their competence (25). The
recent publication of this standard is also likely to explain
our observed shift of the combined ISO 9001 & ISO 20387
intention toward the majority opting for ISO 20387 in the
second survey.
The participants expressed a clear need for a national peer
review program and a self-assessment survey fit to the Belgian
legislation. These requests can be addressed by the BBMRI.be
Quality working group, by developing add-ons to existing or
starting international initiatives in order to harmonize to the
global community. Given the resources available, the initial focus
will be put on the implementation of the audit program, building
on the FBN peer review audit. About half of the responders
indicated a need for a national proficiency testing scheme. It has
been shown that repeated participation in biobank proficiency
schemes can indeed lead to global improvement of performance
(35, 36). However, about half of the responders are currently
not participating in already available proficiency schemes. It
is therefore opted by Quality working group to educate the
biobanks regarding the existence and advantage of proficiency
testing programs as a more valuable first step.
Overall, the biobanks of the BBMRI.be network have actively
implemented a quality approach in their daily practices, though
room for improvement exists. The implementation of ISO20387
may bring further professionalization of activities. Based on the
current needs expressed in this survey, the Quality working
group will be setting up a novel audit program for the
BBMRI.be biobanks, to enhance, harmonize and streamline
activities. Additionally, raising further awareness about self-
assessment tools that are freely available, proficiency testing
schemes and the value of performing these tests will be
on the agenda in the coming months and years. On the
whole, the biobanks in the BBMRI.be network are able to
contribute to better translational research through a sustained
quality approach.
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